前朝 personal page - To The Moon

前朝

No personal profile

17Follow

0Followers

0Topic

0Badge

10-28

＂

Spot gold fell below $3,900/oz! U.S. gold stocks weakened across the board, with Jintian and Harmony gold falling more than 5% before the market.

10-06

，

Tiger Black Market | Changfeng Pharmaceutical soared nearly 97%, winning the lottery and earning more than 7,000 Hong Kong dollars

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4200923741191892","uuid":"4200923741191892","gmtCreate":1737820568910,"gmtModify":1737822775302,"name":"前朝","pinyin":"qcqianchao","introduction":"","introductionEn":null,"signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":17,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":13,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":13,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":494042967683592,"gmtCreate":1761642125010,"gmtModify":1761642127917,"author":{"id":"4200923741191892","authorId":"4200923741191892","name":"前朝","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4200923741191892","authorIdStr":"4200923741191892"},"themes":[],"htmlText":"＂","listText":"＂","text":"＂","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/494042967683592","repostId":"1164101616","repostType":2,"repost":{"id":"1164101616","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1761641963,"share":"https://ttm.financial/m/news/1164101616?lang=en_US&edition=fundamental","pubTime":"2025-10-28 16:59","market":"us","language":"zh","title":"Spot gold fell below $3,900/oz! U.S. gold stocks weakened across the board, with Jintian and Harmony gold falling more than 5% before the market.","url":"https://stock-news.laohu8.com/highlight/detail?id=1164101616","media":"老虎资讯综合","summary":"现货黄金跌破3900美元/盎司关口，日内跌超2%。","content":"<p><html><head></head><body>On October 28, spot gold fell below the US $3,900/oz mark for the first time since October 6, falling more than 2% during the day. In the past six trading days, spot gold recorded a decline in five trading days.</p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/282da0c02bb99d619504c7b440abab5c\" title=\"\" tg-width=\"914\" tg-height=\"434\"/></p><p>U.S. gold stocks continued to weaken before the market,<a href=\"https://laohu8.com/S/GFI\">Jintian</a>、<a href=\"https://laohu8.com/S/HMY\">Harmony Gold</a>、<a href=\"https://laohu8.com/S/AU\">AngloGold Ashanti</a>Fell more than 5%,<a href=\"https://laohu8.com/S/NEM\">Newman Mining</a>、<a href=\"https://laohu8.com/S/B\">Barrick Mining</a>Fell more than 4%.</p><p></body></html></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spot gold fell below $3,900/oz! U.S. gold stocks weakened across the board, with Jintian and Harmony gold falling more than 5% before the market.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpot gold fell below $3,900/oz! U.S. gold stocks weakened across the board, with Jintian and Harmony gold falling more than 5% before the market.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2025-10-28 16:59</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>On October 28, spot gold fell below the US $3,900/oz mark for the first time since October 6, falling more than 2% during the day. In the past six trading days, spot gold recorded a decline in five trading days.</p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/282da0c02bb99d619504c7b440abab5c\" title=\"\" tg-width=\"914\" tg-height=\"434\"/></p><p>U.S. gold stocks continued to weaken before the market,<a href=\"https://laohu8.com/S/GFI\">Jintian</a>、<a href=\"https://laohu8.com/S/HMY\">Harmony Gold</a>、<a href=\"https://laohu8.com/S/AU\">AngloGold Ashanti</a>Fell more than 5%,<a href=\"https://laohu8.com/S/NEM\">Newman Mining</a>、<a href=\"https://laohu8.com/S/B\">Barrick Mining</a>Fell more than 4%.</p><p></body></html></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/a710f0e16d2fb84784400d545feef76f","relate_stocks":{"LU0630314457.HKD":"NINETY ONE GSF GLOBAL NATURAL RESOURCES \"A\" (HKD) ACC","LU2462611646.USD":"AMUNDI FUNDS REAL ASSETS TARGET INCOME \"A2\" (USD) INC MTI","LU0612318385.USD":"BGF NATURAL RESOURCES \"A2\" (USD) ACC","LU2498475776.HKD":"AMUNDI FUNDS REAL ASSETS TARGET INCOME \"A2\" (HKD) INC","LU1223082519.USD":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","LU0345780281.USD":"NINETY ONE GSF GLOBAL GOLD \"A\"  ACC","BK4532":"文艺复兴科技持仓","LU0266512127.USD":"摩根大通环球自然资源 A(acc)","LU0788108826.HKD":"BGF WORLD GOLD \"A2\" (HKDHGD) ACC","BK4570":"地缘局势概念股","LU0498741890.SGD":"FTIF - Franklin Gold and Precious Metals A (acc) SGD","AU":"AngloGold Ashanti Ltd ADS","BK4585":"ETF&股票定投概念","LU0496367417.USD":"富兰克林黄金和贵金属A（acc）","LU0724618789.USD":"BGF WORLD GOLD \"A4\" (USD) INC","SG9999001143.SGD":"United Gold and General A Acc SGD","LU1223083913.SGD":"Schroder ISF Global Gold A Acc SGD-H","GFI":"金田","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0055631609.USD":"贝莱德世界黄金基金A2","LU0278409577.USD":"MANULIFE GLOBAL FUND-GLOBAL RESOURCES FUND \"AA\" (USD) INC","LU0330918003.SGD":"Blackrock World Mining A2 SGD-H","LU0788109121.HKD":"BGF WORLD MINING \"A2\" (HKDHGD) ACC","LU1223082196.USD":"施罗德环球黄金A Acc","BK7104":"黄金","LU1430597077.USD":"BGF NATURAL RESOURCES \"A\" (USD) INC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0075056555.USD":"贝莱德世界矿业基金A2","HMY":"哈莫尼黄金","LU0266512473.USD":"JPM GLOBAL NATURAL RESOURCES \"C\" (USD) ACC","LU0345780950.USD":"NINETY ONE GSF GLOBAL NATURAL RESOURCES \"A\" (USD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1023059493.AUD":"Blackrock World Mining A2 AUD-H","BK7093":"消费信贷","LU0654597011.USD":"BGF NATURAL RESOURCES \"A4G\" (USD) INC","LU1883866441.USD":"AMUNDI FUNDS REAL ASSETS TARGET INCOME \"A2\" (USD) ACC","BK4017":"黄金","LU0368265764.SGD":"Blackrock World Gold Fund A2 SGD-H","LU0300736492.USD":"FRANKLIN NATURAL RESOURCES \"A\" (USD) INC","LU0456854461.SGD":"JPMorgan Funds - Global Natural Resources A (acc) SGD","LU0612318971.USD":"BGF NATURAL RESOURCES \"A5G\" (USD) INC","NEM":"纽曼矿业","BK4588":"碎股","B":"Barrick Mining Corporation","LU0300736062.USD":"FRANKLIN NATURAL RESOURCES \"A\" (USD) ACC","LU0345780521.USD":"NINETY ONE GSF GLOBAL GOLD \"A\" (USD) INC","LU0498741114.HKD":"FRANKLIN GOLD & PRECIOUS METALS \"A\" (HKD) ACC","LU0345781412.USD":"NINETY ONE GSF GLOBAL NATURAL RESOURCES \"A\" (USD) INC"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164101616","content_text":"10月28日，现货黄金跌破3900美元/盎司关口，为10月6日以来首次，日内跌超2%。近6个交易日，现货黄金有5个交易日录得下跌。美股黄金股盘前继续走弱，金田、哈莫尼黄金、AngloGold Ashanti跌超5%，纽曼矿业、Barrick Mining跌超4%。","news_type":1,"symbols_score_info":{"AU":1,"B":1,"NEM":1,"GFI":1,"HMY":1}},"isVote":1,"tweetType":1,"viewCount":49,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":486386071953720,"gmtCreate":1759739154904,"gmtModify":1759739157720,"author":{"id":"4200923741191892","authorId":"4200923741191892","name":"前朝","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4200923741191892","authorIdStr":"4200923741191892"},"themes":[],"htmlText":"&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; ，","listText":"&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; ，","text":"，","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/486386071953720","repostId":"1188965627","repostType":2,"repost":{"id":"1188965627","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1759738530,"share":"https://ttm.financial/m/news/1188965627?lang=en_US&edition=fundamental","pubTime":"2025-10-06 16:15","market":"hk","language":"zh","title":"Tiger Black Market | Changfeng Pharmaceutical soared nearly 97%, winning the lottery and earning more than 7,000 Hong Kong dollars","url":"https://stock-news.laohu8.com/highlight/detail?id=1188965627","media":"老虎资讯综合","summary":"10月6日，$长风药业$暗盘涨近97%，总市值近120亿港元；不计手续费，中签一手赚超7000港元；公司每股定价14.75港元，每手500股，将于10月8日（周三）正式挂牌交易。公司概况长风药业主要专注于吸入技术及吸入药物的研发、生产及商业化，专注于治疗呼吸系统疾病。筹资用途筹资用途方面，长风药业预计全球发售所得款项净额约5.25亿港元。","content":"<p><html><head></head><body>October 6th,<a href=\"https://laohu8.com/S/02652\">Changfeng Pharmaceutical</a>The black market rose nearly 97%, with a total market value of nearly 12 billion Hong Kong dollars; Regardless of handling fees, winning the lottery earns more than HK $7,000; The company is priced at HK $14.75 per share, with 500 shares per lot, and will be officially listed for trading on October 8 (Wednesday).</p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4221acf2e10134a68cd7827679c755c6\" tg-width=\"531\" tg-height=\"630\"/></p><p><strong>Overview of the Company</strong></p><p>Changfeng Pharmaceutical mainly focuses on the research and development, production and commercialization of inhalation technology and inhalation drugs, focusing on the treatment of respiratory diseases. The company has developed a product portfolio covering a wide range of patients, medical specialties and therapeutic areas. During the Track Record Period, the company obtained six product approvals from the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) and earned substantial sales revenue, demonstrating the company's clinical development, production, regulatory affairs and commercialization capabilities.</p><p>CF017, budesonide suspension for inhalation for the treatment of bronchial asthma (the highest selling inhalation drug category in China), is the first approved product of Changfeng Pharmaceutical. After being approved in May 2021, CF017 was quickly included in China's centralized procurement (VBP) plan and achieved market growth. According to Frost & Sullivan, in 2024, CF017 will account for approximately 16% of China's budesonide inhalation drug market in 2024 in terms of sales volume.</p><p><strong>FINANCIAL</strong></p><p>In terms of financial position, for 2022, 2023, 2024 and the three months ended March 31, 2024 and 2025, the company's revenue was RMB 349 million, RMB 556 million, RMB 608 million, and RMB 140 million respectively. RMB 136 million and the company's gross profit was RMB 268 million, RMB 458 million, RMB 491 million, RMB 115 million and RMB 108 million respectively.</p><p><strong>Purpose of financing</strong></p><p>In terms of fund-raising purposes, Changfeng Pharmaceutical expects the net proceeds from the global offering to be approximately HK $525 million (assuming that the over-allotment option is not exercised, based on the offer price of HK $14.75). According to the prospectus, Changfeng Pharmaceutical intends to use the funds raised from the global offering for the following purposes:</p><p>Approximately 40.0% will be used to fund the continuous research and development, clinical development and commercialization of the Group's domestic and international inhalation formulation product candidates; Approximately 20.0% will be used to fund the preclinical research and development of the group's multiple pipeline plans and technologies; Approximately 30.0% will be used to provide funds for the expansion and upgrading of the group's production facilities, equipment procurement and production management systems; Approximately 10.0% will be used for working capital and other general corporate purposes.</p><p></body></html></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tiger Black Market | Changfeng Pharmaceutical soared nearly 97%, winning the lottery and earning more than 7,000 Hong Kong dollars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTiger Black Market | Changfeng Pharmaceutical soared nearly 97%, winning the lottery and earning more than 7,000 Hong Kong dollars\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2025-10-06 16:15</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>October 6th,<a href=\"https://laohu8.com/S/02652\">Changfeng Pharmaceutical</a>The black market rose nearly 97%, with a total market value of nearly 12 billion Hong Kong dollars; Regardless of handling fees, winning the lottery earns more than HK $7,000; The company is priced at HK $14.75 per share, with 500 shares per lot, and will be officially listed for trading on October 8 (Wednesday).</p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4221acf2e10134a68cd7827679c755c6\" tg-width=\"531\" tg-height=\"630\"/></p><p><strong>Overview of the Company</strong></p><p>Changfeng Pharmaceutical mainly focuses on the research and development, production and commercialization of inhalation technology and inhalation drugs, focusing on the treatment of respiratory diseases. The company has developed a product portfolio covering a wide range of patients, medical specialties and therapeutic areas. During the Track Record Period, the company obtained six product approvals from the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) and earned substantial sales revenue, demonstrating the company's clinical development, production, regulatory affairs and commercialization capabilities.</p><p>CF017, budesonide suspension for inhalation for the treatment of bronchial asthma (the highest selling inhalation drug category in China), is the first approved product of Changfeng Pharmaceutical. After being approved in May 2021, CF017 was quickly included in China's centralized procurement (VBP) plan and achieved market growth. According to Frost & Sullivan, in 2024, CF017 will account for approximately 16% of China's budesonide inhalation drug market in 2024 in terms of sales volume.</p><p><strong>FINANCIAL</strong></p><p>In terms of financial position, for 2022, 2023, 2024 and the three months ended March 31, 2024 and 2025, the company's revenue was RMB 349 million, RMB 556 million, RMB 608 million, and RMB 140 million respectively. RMB 136 million and the company's gross profit was RMB 268 million, RMB 458 million, RMB 491 million, RMB 115 million and RMB 108 million respectively.</p><p><strong>Purpose of financing</strong></p><p>In terms of fund-raising purposes, Changfeng Pharmaceutical expects the net proceeds from the global offering to be approximately HK $525 million (assuming that the over-allotment option is not exercised, based on the offer price of HK $14.75). According to the prospectus, Changfeng Pharmaceutical intends to use the funds raised from the global offering for the following purposes:</p><p>Approximately 40.0% will be used to fund the continuous research and development, clinical development and commercialization of the Group's domestic and international inhalation formulation product candidates; Approximately 20.0% will be used to fund the preclinical research and development of the group's multiple pipeline plans and technologies; Approximately 30.0% will be used to provide funds for the expansion and upgrading of the group's production facilities, equipment procurement and production management systems; Approximately 10.0% will be used for working capital and other general corporate purposes.</p><p></body></html></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab","relate_stocks":{"02652":"长风药业"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188965627","content_text":"10月6日，长风药业暗盘涨近97%，总市值近120亿港元；不计手续费，中签一手赚超7000港元；公司每股定价14.75港元，每手500股，将于10月8日（周三）正式挂牌交易。公司概况长风药业主要专注于吸入技术及吸入药物的研发、生产及商业化，专注于治疗呼吸系统疾病。公司已开发出覆盖广泛患者、医学专科及治疗领域的产品组合。于往绩记录期间，公司自国家药品监督管理局（国家药监局）及美国食品药品监督管理局(FDA)获得六项产品批准并赚取大量销售收益，彰显公司在临床开发、生产、监管事务及商业化方面的能力。CF017，即治疗支气管哮喘的吸入用布地奈德混悬液（中国销量最高的吸入药物类别），为长风药业的首个获批产品。2021年5月获批后，CF017迅速纳入中国集中採购(VBP)计划，并实现了市场增长。根据弗若斯特沙利文的资料，于2024年，按销量计，CF017占2024年中国布地奈德吸入药物市场约16%。财务概况财务状况方面，于2022年、2023年、2024年及截至2024年及2025年3月31日止三个月，公司的收益分别为人民币3.49亿元、人民币5.56亿元、人民币6.08亿元、人民币1.4亿元及人民币1.36亿元，公司的毛利分别为人民币2.68亿元、人民币4.58亿元、人民币4.91亿元、人民币1.15亿元及人民币1.08亿元。筹资用途筹资用途方面，长风药业预计全球发售所得款项净额约5.25亿港元（假设超额配售选择权未获行使，以发售价14.75港元计算）。根据招股书，长风药业拟将全球发售募集资金用于下述用途：约40.0%将用于为集团国内及国际的吸入制剂候选产品的持续研发、临床开发及商业化提供资金；约20.0%将用于为集团多个管线计划及技术的临床前研发提供资金；约30.0%将用于为集团生产设施、设备采购及生产管理系统的扩张及升级提供资金；约10.0%将用作营运资金及其他一般公司用途。","news_type":1,"symbols_score_info":{"02652":1.5}},"isVote":1,"tweetType":1,"viewCount":68,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":494042967683592,"gmtCreate":1761642125010,"gmtModify":1761642127917,"author":{"id":"4200923741191892","authorId":"4200923741191892","name":"前朝","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4200923741191892","idStr":"4200923741191892"},"themes":[],"htmlText":"＂","listText":"＂","text":"＂","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/494042967683592","repostId":"1164101616","repostType":2,"repost":{"id":"1164101616","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1761641963,"share":"https://ttm.financial/m/news/1164101616?lang=en_US&edition=fundamental","pubTime":"2025-10-28 16:59","market":"us","language":"zh","title":"Spot gold fell below $3,900/oz! U.S. gold stocks weakened across the board, with Jintian and Harmony gold falling more than 5% before the market.","url":"https://stock-news.laohu8.com/highlight/detail?id=1164101616","media":"老虎资讯综合","summary":"现货黄金跌破3900美元/盎司关口，日内跌超2%。","content":"<p><html><head></head><body>On October 28, spot gold fell below the US $3,900/oz mark for the first time since October 6, falling more than 2% during the day. In the past six trading days, spot gold recorded a decline in five trading days.</p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/282da0c02bb99d619504c7b440abab5c\" title=\"\" tg-width=\"914\" tg-height=\"434\"/></p><p>U.S. gold stocks continued to weaken before the market,<a href=\"https://laohu8.com/S/GFI\">Jintian</a>、<a href=\"https://laohu8.com/S/HMY\">Harmony Gold</a>、<a href=\"https://laohu8.com/S/AU\">AngloGold Ashanti</a>Fell more than 5%,<a href=\"https://laohu8.com/S/NEM\">Newman Mining</a>、<a href=\"https://laohu8.com/S/B\">Barrick Mining</a>Fell more than 4%.</p><p></body></html></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spot gold fell below $3,900/oz! U.S. gold stocks weakened across the board, with Jintian and Harmony gold falling more than 5% before the market.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpot gold fell below $3,900/oz! U.S. gold stocks weakened across the board, with Jintian and Harmony gold falling more than 5% before the market.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2025-10-28 16:59</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>On October 28, spot gold fell below the US $3,900/oz mark for the first time since October 6, falling more than 2% during the day. In the past six trading days, spot gold recorded a decline in five trading days.</p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/282da0c02bb99d619504c7b440abab5c\" title=\"\" tg-width=\"914\" tg-height=\"434\"/></p><p>U.S. gold stocks continued to weaken before the market,<a href=\"https://laohu8.com/S/GFI\">Jintian</a>、<a href=\"https://laohu8.com/S/HMY\">Harmony Gold</a>、<a href=\"https://laohu8.com/S/AU\">AngloGold Ashanti</a>Fell more than 5%,<a href=\"https://laohu8.com/S/NEM\">Newman Mining</a>、<a href=\"https://laohu8.com/S/B\">Barrick Mining</a>Fell more than 4%.</p><p></body></html></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/a710f0e16d2fb84784400d545feef76f","relate_stocks":{"LU0630314457.HKD":"NINETY ONE GSF GLOBAL NATURAL RESOURCES \"A\" (HKD) ACC","LU2462611646.USD":"AMUNDI FUNDS REAL ASSETS TARGET INCOME \"A2\" (USD) INC MTI","LU0612318385.USD":"BGF NATURAL RESOURCES \"A2\" (USD) ACC","LU2498475776.HKD":"AMUNDI FUNDS REAL ASSETS TARGET INCOME \"A2\" (HKD) INC","LU1223082519.USD":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","LU0345780281.USD":"NINETY ONE GSF GLOBAL GOLD \"A\"  ACC","BK4532":"文艺复兴科技持仓","LU0266512127.USD":"摩根大通环球自然资源 A(acc)","LU0788108826.HKD":"BGF WORLD GOLD \"A2\" (HKDHGD) ACC","BK4570":"地缘局势概念股","LU0498741890.SGD":"FTIF - Franklin Gold and Precious Metals A (acc) SGD","AU":"AngloGold Ashanti Ltd ADS","BK4585":"ETF&股票定投概念","LU0496367417.USD":"富兰克林黄金和贵金属A（acc）","LU0724618789.USD":"BGF WORLD GOLD \"A4\" (USD) INC","SG9999001143.SGD":"United Gold and General A Acc SGD","LU1223083913.SGD":"Schroder ISF Global Gold A Acc SGD-H","GFI":"金田","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0055631609.USD":"贝莱德世界黄金基金A2","LU0278409577.USD":"MANULIFE GLOBAL FUND-GLOBAL RESOURCES FUND \"AA\" (USD) INC","LU0330918003.SGD":"Blackrock World Mining A2 SGD-H","LU0788109121.HKD":"BGF WORLD MINING \"A2\" (HKDHGD) ACC","LU1223082196.USD":"施罗德环球黄金A Acc","BK7104":"黄金","LU1430597077.USD":"BGF NATURAL RESOURCES \"A\" (USD) INC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0075056555.USD":"贝莱德世界矿业基金A2","HMY":"哈莫尼黄金","LU0266512473.USD":"JPM GLOBAL NATURAL RESOURCES \"C\" (USD) ACC","LU0345780950.USD":"NINETY ONE GSF GLOBAL NATURAL RESOURCES \"A\" (USD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1023059493.AUD":"Blackrock World Mining A2 AUD-H","BK7093":"消费信贷","LU0654597011.USD":"BGF NATURAL RESOURCES \"A4G\" (USD) INC","LU1883866441.USD":"AMUNDI FUNDS REAL ASSETS TARGET INCOME \"A2\" (USD) ACC","BK4017":"黄金","LU0368265764.SGD":"Blackrock World Gold Fund A2 SGD-H","LU0300736492.USD":"FRANKLIN NATURAL RESOURCES \"A\" (USD) INC","LU0456854461.SGD":"JPMorgan Funds - Global Natural Resources A (acc) SGD","LU0612318971.USD":"BGF NATURAL RESOURCES \"A5G\" (USD) INC","NEM":"纽曼矿业","BK4588":"碎股","B":"Barrick Mining Corporation","LU0300736062.USD":"FRANKLIN NATURAL RESOURCES \"A\" (USD) ACC","LU0345780521.USD":"NINETY ONE GSF GLOBAL GOLD \"A\" (USD) INC","LU0498741114.HKD":"FRANKLIN GOLD & PRECIOUS METALS \"A\" (HKD) ACC","LU0345781412.USD":"NINETY ONE GSF GLOBAL NATURAL RESOURCES \"A\" (USD) INC"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164101616","content_text":"10月28日，现货黄金跌破3900美元/盎司关口，为10月6日以来首次，日内跌超2%。近6个交易日，现货黄金有5个交易日录得下跌。美股黄金股盘前继续走弱，金田、哈莫尼黄金、AngloGold Ashanti跌超5%，纽曼矿业、Barrick Mining跌超4%。","news_type":1,"symbols_score_info":{"AU":1,"B":1,"NEM":1,"GFI":1,"HMY":1}},"isVote":1,"tweetType":1,"viewCount":49,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":486386071953720,"gmtCreate":1759739154904,"gmtModify":1759739157720,"author":{"id":"4200923741191892","authorId":"4200923741191892","name":"前朝","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4200923741191892","idStr":"4200923741191892"},"themes":[],"htmlText":"&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; ，","listText":"&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; ，","text":"，","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/486386071953720","repostId":"1188965627","repostType":2,"repost":{"id":"1188965627","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1759738530,"share":"https://ttm.financial/m/news/1188965627?lang=en_US&edition=fundamental","pubTime":"2025-10-06 16:15","market":"hk","language":"zh","title":"Tiger Black Market | Changfeng Pharmaceutical soared nearly 97%, winning the lottery and earning more than 7,000 Hong Kong dollars","url":"https://stock-news.laohu8.com/highlight/detail?id=1188965627","media":"老虎资讯综合","summary":"10月6日，$长风药业$暗盘涨近97%，总市值近120亿港元；不计手续费，中签一手赚超7000港元；公司每股定价14.75港元，每手500股，将于10月8日（周三）正式挂牌交易。公司概况长风药业主要专注于吸入技术及吸入药物的研发、生产及商业化，专注于治疗呼吸系统疾病。筹资用途筹资用途方面，长风药业预计全球发售所得款项净额约5.25亿港元。","content":"<p><html><head></head><body>October 6th,<a href=\"https://laohu8.com/S/02652\">Changfeng Pharmaceutical</a>The black market rose nearly 97%, with a total market value of nearly 12 billion Hong Kong dollars; Regardless of handling fees, winning the lottery earns more than HK $7,000; The company is priced at HK $14.75 per share, with 500 shares per lot, and will be officially listed for trading on October 8 (Wednesday).</p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4221acf2e10134a68cd7827679c755c6\" tg-width=\"531\" tg-height=\"630\"/></p><p><strong>Overview of the Company</strong></p><p>Changfeng Pharmaceutical mainly focuses on the research and development, production and commercialization of inhalation technology and inhalation drugs, focusing on the treatment of respiratory diseases. The company has developed a product portfolio covering a wide range of patients, medical specialties and therapeutic areas. During the Track Record Period, the company obtained six product approvals from the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) and earned substantial sales revenue, demonstrating the company's clinical development, production, regulatory affairs and commercialization capabilities.</p><p>CF017, budesonide suspension for inhalation for the treatment of bronchial asthma (the highest selling inhalation drug category in China), is the first approved product of Changfeng Pharmaceutical. After being approved in May 2021, CF017 was quickly included in China's centralized procurement (VBP) plan and achieved market growth. According to Frost & Sullivan, in 2024, CF017 will account for approximately 16% of China's budesonide inhalation drug market in 2024 in terms of sales volume.</p><p><strong>FINANCIAL</strong></p><p>In terms of financial position, for 2022, 2023, 2024 and the three months ended March 31, 2024 and 2025, the company's revenue was RMB 349 million, RMB 556 million, RMB 608 million, and RMB 140 million respectively. RMB 136 million and the company's gross profit was RMB 268 million, RMB 458 million, RMB 491 million, RMB 115 million and RMB 108 million respectively.</p><p><strong>Purpose of financing</strong></p><p>In terms of fund-raising purposes, Changfeng Pharmaceutical expects the net proceeds from the global offering to be approximately HK $525 million (assuming that the over-allotment option is not exercised, based on the offer price of HK $14.75). According to the prospectus, Changfeng Pharmaceutical intends to use the funds raised from the global offering for the following purposes:</p><p>Approximately 40.0% will be used to fund the continuous research and development, clinical development and commercialization of the Group's domestic and international inhalation formulation product candidates; Approximately 20.0% will be used to fund the preclinical research and development of the group's multiple pipeline plans and technologies; Approximately 30.0% will be used to provide funds for the expansion and upgrading of the group's production facilities, equipment procurement and production management systems; Approximately 10.0% will be used for working capital and other general corporate purposes.</p><p></body></html></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tiger Black Market | Changfeng Pharmaceutical soared nearly 97%, winning the lottery and earning more than 7,000 Hong Kong dollars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTiger Black Market | Changfeng Pharmaceutical soared nearly 97%, winning the lottery and earning more than 7,000 Hong Kong dollars\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2025-10-06 16:15</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>October 6th,<a href=\"https://laohu8.com/S/02652\">Changfeng Pharmaceutical</a>The black market rose nearly 97%, with a total market value of nearly 12 billion Hong Kong dollars; Regardless of handling fees, winning the lottery earns more than HK $7,000; The company is priced at HK $14.75 per share, with 500 shares per lot, and will be officially listed for trading on October 8 (Wednesday).</p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4221acf2e10134a68cd7827679c755c6\" tg-width=\"531\" tg-height=\"630\"/></p><p><strong>Overview of the Company</strong></p><p>Changfeng Pharmaceutical mainly focuses on the research and development, production and commercialization of inhalation technology and inhalation drugs, focusing on the treatment of respiratory diseases. The company has developed a product portfolio covering a wide range of patients, medical specialties and therapeutic areas. During the Track Record Period, the company obtained six product approvals from the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) and earned substantial sales revenue, demonstrating the company's clinical development, production, regulatory affairs and commercialization capabilities.</p><p>CF017, budesonide suspension for inhalation for the treatment of bronchial asthma (the highest selling inhalation drug category in China), is the first approved product of Changfeng Pharmaceutical. After being approved in May 2021, CF017 was quickly included in China's centralized procurement (VBP) plan and achieved market growth. According to Frost & Sullivan, in 2024, CF017 will account for approximately 16% of China's budesonide inhalation drug market in 2024 in terms of sales volume.</p><p><strong>FINANCIAL</strong></p><p>In terms of financial position, for 2022, 2023, 2024 and the three months ended March 31, 2024 and 2025, the company's revenue was RMB 349 million, RMB 556 million, RMB 608 million, and RMB 140 million respectively. RMB 136 million and the company's gross profit was RMB 268 million, RMB 458 million, RMB 491 million, RMB 115 million and RMB 108 million respectively.</p><p><strong>Purpose of financing</strong></p><p>In terms of fund-raising purposes, Changfeng Pharmaceutical expects the net proceeds from the global offering to be approximately HK $525 million (assuming that the over-allotment option is not exercised, based on the offer price of HK $14.75). According to the prospectus, Changfeng Pharmaceutical intends to use the funds raised from the global offering for the following purposes:</p><p>Approximately 40.0% will be used to fund the continuous research and development, clinical development and commercialization of the Group's domestic and international inhalation formulation product candidates; Approximately 20.0% will be used to fund the preclinical research and development of the group's multiple pipeline plans and technologies; Approximately 30.0% will be used to provide funds for the expansion and upgrading of the group's production facilities, equipment procurement and production management systems; Approximately 10.0% will be used for working capital and other general corporate purposes.</p><p></body></html></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab","relate_stocks":{"02652":"长风药业"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188965627","content_text":"10月6日，长风药业暗盘涨近97%，总市值近120亿港元；不计手续费，中签一手赚超7000港元；公司每股定价14.75港元，每手500股，将于10月8日（周三）正式挂牌交易。公司概况长风药业主要专注于吸入技术及吸入药物的研发、生产及商业化，专注于治疗呼吸系统疾病。公司已开发出覆盖广泛患者、医学专科及治疗领域的产品组合。于往绩记录期间，公司自国家药品监督管理局（国家药监局）及美国食品药品监督管理局(FDA)获得六项产品批准并赚取大量销售收益，彰显公司在临床开发、生产、监管事务及商业化方面的能力。CF017，即治疗支气管哮喘的吸入用布地奈德混悬液（中国销量最高的吸入药物类别），为长风药业的首个获批产品。2021年5月获批后，CF017迅速纳入中国集中採购(VBP)计划，并实现了市场增长。根据弗若斯特沙利文的资料，于2024年，按销量计，CF017占2024年中国布地奈德吸入药物市场约16%。财务概况财务状况方面，于2022年、2023年、2024年及截至2024年及2025年3月31日止三个月，公司的收益分别为人民币3.49亿元、人民币5.56亿元、人民币6.08亿元、人民币1.4亿元及人民币1.36亿元，公司的毛利分别为人民币2.68亿元、人民币4.58亿元、人民币4.91亿元、人民币1.15亿元及人民币1.08亿元。筹资用途筹资用途方面，长风药业预计全球发售所得款项净额约5.25亿港元（假设超额配售选择权未获行使，以发售价14.75港元计算）。根据招股书，长风药业拟将全球发售募集资金用于下述用途：约40.0%将用于为集团国内及国际的吸入制剂候选产品的持续研发、临床开发及商业化提供资金；约20.0%将用于为集团多个管线计划及技术的临床前研发提供资金；约30.0%将用于为集团生产设施、设备采购及生产管理系统的扩张及升级提供资金；约10.0%将用作营运资金及其他一般公司用途。","news_type":1,"symbols_score_info":{"02652":1.5}},"isVote":1,"tweetType":1,"viewCount":68,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}